At the archive date, BRISTOL MYERS SQUIBB CO was expected to release its Q3 2026 10-Q filing on October 29, 2026. Last quarter: In Q2 FY2026, Bristol-Myers Squibb delivered strong financial results with revenue growing 5.7% YoY to $12.97B and net income surging 153.2% YoY to $3.32B, driven by 15% growth in its new product portfolio and reduced Acquired IPRD charges.
EPS Estimate
$1.74
Revenue Estimate
$12.68B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the BMY page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Total Growth Portfolio revenue rose 15% YoY to $7.56B in Q2 FY2026, powered by strong performances from Camzyos (+60% to $416M), Breyanzi (+41% to $484M), and Reblozyl (+29% to $735M). This growth helped offset a 4% decline in Legacy Portfolio revenue ($5.42B) caused by generic erosion in Revlimid (-49% to $425M) and Pomalyst (-71% to $204M).
Eliquis revenues increased 22% YoY to $4.48B in Q2 FY2026, supported by higher demand and higher average net selling prices in the U.S., where a list price reduction resulted in lower gross-to-net rebates.
The U.S. HHS established 'maximum fair prices' under the Inflation Reduction Act for Eliquis (effective January 2026) and Pomalyst (effective January 2027) in Medicare, while Orencia was selected in January 2026 for price negotiations taking effect in 2028.
Revenue
$12.97B
+5.74% YoY
EPS (Diluted)
$1.62
+153.13% YoY
Add BMY to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.